Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus neoadjuvant chemoradiation for thoracic esophageal squamous cell carcinoma
ChiCTR2100042530Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoints: Pathological complete remission rate, Main pathological response rate and 3 more. Started Oct 2020; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100042530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042530.